Skip to main content

Table 3 Invasive disease-free survival according to UGT2B7His268Tyr genotype and treatment

From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

  Hazard ratio (95% CI)
Adjuvant chemotherapy Crude Adjusted
Epirubicin 2.24 (1.13 to 4.44) 2.64 (1.22 to 5.71)
  P = 0.021 P = 0.014
Epirubicin/tamoxifen 4.43 (1.34 to 14.6) 5.22 (1.67-26.04)
  P = 0.015 P = 0.015)
No epirubicin 0.80 (0.43 to 1.49) 0.78 (0.40 to 1.50)
  P = 0.48 P = 0.45
None 0.80 (0.47 to 1.34) 0.87 (0.49 to 1.55)
  P = 0.39 P = 0.64
  1. CI, confidence interval.